SANTA CLARA, Calif.,
June 17, 2011 /PRNewswire/ --
NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology
provider, announced today that Vincent
Renz, Chief Executive Officer, is scheduled to present at
the Wells Fargo Securities Healthcare Conference. The Conference is
on June 22 and 23, 2011, at The
InterContinental Boston. Mr. Renz' presentation is scheduled for
3:30 p.m. ET on Wednesday, June 22.
Investors planning to attend the conference should contact their
Wells Fargo representative to arrange a meeting.
About Wells Fargo
Wells Fargo Advisors is a non-bank affiliate of Wells Fargo
& Company, providing advisory services, asset management,
brokerage services, estate planning strategies, retirement
planning, portfolio analysis and monitoring, and other financial
services through more than 19,000 registered representatives.
Wells Fargo & Company is a nationwide, diversified,
community-based financial services company with $1.2 trillion in assets. Founded in 1852 and
headquartered in San Francisco, Wells Fargo provides
banking, insurance, investments, mortgage, and consumer and
commercial finance through more than 9,000 stores, 12,000 ATMs, the
Internet (wellsfargo.com and wachovia.com), and other distribution
channels across North America and
internationally. With approximately 280,000 team
members, Wells Fargo serves one in three households in
America. Wells Fargo & Company was ranked No. 19
on Fortune's 2010 rankings of America's largest
corporations.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company
developing and marketing proprietary software platform technologies
to provide higher accuracy to, and increase the value of, the
standard 12-lead ECG. NewCardio's 3D ECG software platform
reduces the time and expense involved in assessing cardiac status
while increasing the ability to diagnose clinically significant
conditions which were previously difficult to detect.
NewCardio's software products and services significantly
improve the diagnosis and monitoring of cardiovascular disease, as
well as cardiac safety assessment of drugs under development. For
more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements include, but are not limited to,
statements that express our intentions, beliefs, expectations,
strategies, predictions or any other statements relating to our
future activities or other future events or conditions. These
statements are based on current expectations, estimates and
projections about our business based on currently available
information and assumptions made by management. Although we believe
that the assumptions on which the forward-looking statements
contained herein are based are reasonable, any of those assumptions
could prove to be inaccurate given the inherent uncertainties as to
the occurrence or nonoccurrence of future events. These statements
are not guarantees of future performance and involve risks and
uncertainties that are difficult to predict. Therefore, actual
outcomes and results may, and are likely to, differ materially from
what is expressed or forecasted in the forward-looking statements
due to numerous factors, including the potential risks and
uncertainties set forth in Item 1A of our Annual Report on Form
10-K for the year ended December 31,
2010 and relate to our business plan, our business strategy,
development of our proprietary technology platform and our
products, timing of such development, timing and results of
clinical trials, level and timing of FDA regulatory clearance or
review, market acceptance of our products, protection of our
intellectual property, implementation of our strategic, operating
and people initiatives, benefits to be derived from personnel and
directors, ability to commercialize our products, our assumptions
regarding cash flow from operations and cash on-hand, the amount
and timing of operating costs and capital expenditures relating to
the expansion of our business, operations and infrastructure,
implementation of marketing programs, our key agreements and
strategic alliances, our ability to obtain additional capital as,
and when, needed, and on acceptable terms and general economic
conditions specific to our industry, any of which could impact
sales, costs and expenses and/or planned strategies and timing. We
assume no obligation to, and do not currently intend to, update
these forward-looking statements.
To join our email distribution please click this link:
http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Investor Contact:
Hayden IR
Jeff Stanlis, Partner
(602) 476-1821
jeff@haydenir.com
SOURCE NewCardio, Inc.
